LAS VEGAS, May 12, 2021 DelveInsight’s Diabetic Retinopathy Market Insights report offers detailed information on current treatment practices, emerging drugs, Diabetic Retinopathy market share of the individual therapies, current and forecasted Diabetic Retinopathy market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Some of the key takeaways from the Diabetic Retinopathy Market Insights:
The total diagnosed Diabetic Retinopathy prevalent population in the 7MM countries was estimated to be 8,033,083 cases in 2020.
The United States accounted for the highest percentage of Diabetic Retinopathy prevalent in the population.
Anti-vascular endothelial growth factor (anti-VEGF) drugs including Aflibercept (Eylea from Regeneron and Bayer), Ranibizumab (Lucentis from Genentech and Novartis), and Bevacizumab (Avastin from Genentech) are considered the first line of therapy for the treatment.
Currently, Aflibercept is the accepted standard of care and the market-leading drug in virtually all retinal disorders. Interestingly, Bevacizumab is used off label in ocular indications but is widely reimbursed.
The reasons for choosing one anti-VEGF over another are multifactorial and include retinal thickness, disease progression, best-corrected visual acuity (BCVA), reimbursement, and patient and family influences.
Among the 7MM, the US accounted for 57.0% of the overall Diabetic Retinopathy market size in 2020.
The Diabetic Retinopathy market has a lot of opportunities for biosimilars and novel biochemical pathways.
Novartis Pharmaceuticals (Brolucizumabt), Roche (Faricimab), Adverum Biotechnologies (ADVM-022), Kubota Vision (Emixustat Hydrochloride), KalVista Pharmaceuticals (KVD001), Kodiak Sciences (KSI-301), and others.
However, the expected patents expiries of Aflibercept (in 2022) and Ranibizumab (in 2023), along with the potential launch of biosimilars is expected to dilute the market share of these drugs.
The expected launch of pipeline therapies such as Faricimab, Brolucizumab, Emixustat Hydrochloride, ADVM-022, and KSI-301 during the forecast period (2021–2030) shall create a lot of buzz in the market and push the market size growth further.
Phase II assets include ADVM-022, Emixustat Hydrochloride, along with Risuteganib.
Owing to rising awareness and understanding of the disease, favourable conditions for novel anti-infective modalities are expected to lead more pharma companies to set their feet in the Diabetic Retinopathy therapy market, thus, expanding the market size.
Download report to know which drug is going to capture the maximum market share @ Diabetic Retinopathy Market Analysis and Forecast
Diabetic Retinopathy: Disease Overview
Diabetic Retinopathy is a significant complication of diabetes mellitus, which is a leading cause of visual loss in working-age populations. With an increasing prevalence of diabetes, it appears that the prevalence of Diabetic Retinopathy is also on the rise. Type 2 diabetes, which is becoming more common, leads to over 60% of patients diagnosing with Diabetic Retinopathy within the first 20 years of onset.
Furthermore, Age is a noteworthy risk factor for Diabetic Retinopathy prevalence as the chances increase with the age.
Diabetic Retinopathy Epidemiology Segmentation
Diabetic Retinopathy Market and Epidemiology Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:
Total Diagnosed Diabetic Retinopathy Prevalent Cases
Gender-Specific Diabetic Retinopathy Cases
Age-Specific Diabetic Retinopathy Cases
Severity-Specific Diabetic Retinopathy Cases
The report proffers a holistic view of the present Diabetic Retinopathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market’s hidden potential, and plans strategically to handle market risks.
For a comprehensive analysis, visit Diabetic Retinopathy Epidemiological Analysis and Changing Trends
Diabetic Retinopathy Therapy Market
The present scenario in the Diabetic Retinopathy therapeutic landscape appears quite confined, limited to laser treatment, eye injections, and anti-VEGF drugs, which are the preferred first line of therapy. The treatments for DR relies heavily on the presence of macular edema.
Available anti-VEGF drugs include aflibercept (Eylea from Regeneron and Bayer), ranibizumab (Lucentis from Genentech and Novartis), and bevacizumab (Avastin from Genentech) that are presently enjoying the monopoly in the Diabetic Retinopathy market.
However, there exist several gaps in the Diabetic Retinopathy therapeutic market in the form of an absence of biomarkers, a lack of technologies that are potential enough to predict the disease course in patients, and novel pathways to offer novel treatments.
Reach out to us @ Diabetic Retinopathy Marketed Therapies for more information on available treatment regimens
Diabetic Retinopathy Market
The Diabetic Retinopathy market encompasses several novel pipeline therapies with better efficiency and tolerability than conventional and available therapies. Key companies such as Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Kubota Vision, Allegro Ophthalmics, and several others are developing new drugs that project a promising picture of the Diabetic Retinopathy market landscape in the coming decade.
The market has limited options to offer, and a lack of gene therapy, personalized treatment approaches offer pharma companies a latitude to explore and penetrate with novel gene therapies, biosimilars into the market.
This does not only promise one-time treatment but also facilitates the usage of lower doses ascribed to favorable anatomy of the eye owing to its size. Moreover, an increasing patient pool also gives pharma companies room for making cost-effective drugs without compromising with gains. Different possible pathways have been extensively studied, which could be responsible for the disease. Therefore, a better understanding has been obtained through years of thorough research and development. The emergence of personalized medications is expected to further drive the growth of the DR market share.
Diabetic Retinopathy Pipeline Therapies and Key Companies
Brolucizumabt: Novartis Pharmaceuticals
ADVM-022: Adverum Biotechnologies
Emixustat Hydrochloride: Kubota Vision
KVD001: KalVista Pharmaceuticals
Get a detailed analysis of Diabetic Retinopathy Emerging Drug Pipeline and Key Companies
Scope of the Report
Coverage: 7MM (the US, EU5, and Japan)
Study Period: 2018-30
Key Companies: Novartis, Roche, Adverum Biotechnologies, Kubota Vision, Kodiak Sciences andAllegro Ophthalmics.
Key Diabetic Retinopathy Pipeline Therapies: Brolucizumab, Faricimab, ADVM-022, Emixustat Hydrochloride, KVD001, KSI-301 and Risuteganib.
Diabetic Retinopathy Market Segmentation: By Geography, By Diabetic Retinopathy Therapies
Analysis: Comparative and conjoint analysis of Diabetic Retinopathy emerging therapies
Tools used: SWOT analysis, Conjoint Analysis, Porter’s Five Forces, PESTLE analysis, BCG Matrix analysis methods.
Drop by to learn more about the future market trends @ Diabetic Retinopathy Market Landscape and Forecast
Table of Contents
Take a tour of the report @ Diabetic Retinopathy Market Forecast and Trends
Skim Through Related Reports and Posts
Diabetic Foot Market
DelveInsight’s “Diabetic Foot – Market Insights, Epidemiology, and Market Forecast-2030” report.
Diabetic Foot Ulcers Market
DelveInsight’s ‘Diabetic Foot Ulcer (DFU) – Market Insights, Epidemiology, and Market Forecast—2030’ report offers detailed analysis into epidemiology, treatment landscape and market covering key pharma companies including TissueTech, Aurealis Therapeutics, Rheacell, Oneness Biotech, Biotherapy Services, HelixMith, Lakewood-Amedex, Mallinckrodt, and many others.
Diabetic Gastroparesis Market Size
DelveInsight’s ‘Diabetic Gastroparesis (DGp) – Market Insights, Epidemiology and Market Forecast-2030 report offers detailed analysis into disease overview (what is diabetic gastroparesis), epidemiology, treatment landscape and market covering key pharma companies including Allergan Evoke Pharma Inc., Theravance Biopharma, Censa Pharmaceuticals, CinDome Pharma, Takeda (Millennium Pharmaceuticals, Inc.), Bird Rock Bio, and others.
Diabetic Ketoacidosis Market
DelveInsight’s “Diabetic Ketoacidosis (DKA) – Market Insights, Epidemiology, and Market Forecast-2030” report.
Diabetic Kidney Disease Market
DelveInsight’s “Diabetic Kidney Disease (DKD) – Market Insights, Epidemiology, and Market Forecast-2030” report.
Diabetic Macular Edema Market
DelveInsight’s “Diabetic Macular Edema (DME) – Market Insights, Epidemiology, and Market Forecast-2030” report offers detailed analysis into epidemiology, treatment landscape and market covering key pharma companies including Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Ocuphire Pharma, Oxurion, and others.
Diabetic Peripheral Neuropathy Market Landscape
Get a detailed analysis of the Diabetic Peripheral Neuropathy (DPN) market landscape, emerging drugs, and key companies involved such as Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmaceuticals, Novaremed Ltd., Grünenthal GmbH, Glenmark Pharmaceuticals, and many others.
Understanding The Increasing Prevalence Of Diabetes And Its Complications
Diabetic Peripheral Neuropathy Market Landscape
Diabetic Peripheral Neuropathy Medications
Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions